Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.75.

Several analysts have recently issued reports on ATRA shares. RODMAN&RENSHAW cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 price target for the company. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $17.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, March 11th.

Atara Biotherapeutics Trading Down 1.6 %

Shares of NASDAQ:ATRA opened at $6.63 on Friday. Atara Biotherapeutics has a 12-month low of $5.40 and a 12-month high of $20.81. The stock’s 50-day moving average price is $8.04 and its two-hundred day moving average price is $9.71. The firm has a market cap of $38.85 million, a price-to-earnings ratio of -0.26 and a beta of 0.49.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.82) by $2.63. The company had revenue of $32.75 million during the quarter, compared to analyst estimates of $20.58 million. As a group, research analysts forecast that Atara Biotherapeutics will post -10.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of large investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics during the 4th quarter worth approximately $48,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics during the fourth quarter valued at approximately $169,000. Citadel Advisors LLC lifted its position in shares of Atara Biotherapeutics by 2.6% during the fourth quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock worth $3,558,000 after purchasing an additional 6,873 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Atara Biotherapeutics by 0.8% during the fourth quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock worth $2,731,000 after purchasing an additional 1,543 shares in the last quarter. Finally, Northern Trust Corp purchased a new position in shares of Atara Biotherapeutics in the fourth quarter valued at $149,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.